Clinical trial

NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC

NCT07318636

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention PD-1 antibody Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention NK010 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC

Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-01-20

PhasePHASE1

Conditions

Resectable Non-small Cell Lung Cancerunresolved

Interventions

PD-1 antibodyDRUG

NK010BIOLOGICAL

Sponsors & collaborators

The First Affiliated Hospital of Guangzhou Medical Universitylead sponsor

Shanghai NK Cell Technology Co., LTDcollaborator

Mapped research locations

GuangzhouGuangdong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07318636 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.